SDC1 and Miyoshi myopathy: Thirdly, treatment of MM cell lines and SYND1 (CD138)+ MM cells with bortezomib and the novel agents lenalidomide (immunomodulatory agent from Celgene, USA) or CDDO-Imidazolide (a triterpenoid initially synthesized by Honda et al., Dartmouth College, USA) induces synergistic anti-MM activity in vitro and overcomes resistance to bortezomib by targeting both intrinsic and extrinsic apoptotic signaling.